

#9 1652
7/31/03

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 01 2003

TECH CENTER 1600/2900

In re Application of:

Oron YACOBY-ZEEVI

Serial No.: 09/978,297

Filed: October 17, 2001

For: Methods of and Pharmaceutical Compositions for
Improving Implantation of Embryos

Examiner: Richard G. Hutson

§
§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1652

Attorney

Docket: 01/22716

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office
Washington, D.C. 20231

Sir:

In accordance with 37 CFR 1.97, we enclose a copy of the following PTO Form SB/08A listing references which may be material to the patentability of the present application.

Also enclosed are copies of the references cited. These are being submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Inasmuch as this Supplemental Information Disclosure Statement is filed after the mailing of the first office action, the fee of \$ 180.- is required. Please charge the fee of \$ 180.-, and any additional fees due to Deposit Account **50-1407**.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Sol Sheinbein', written in a cursive style.

Sol Sheinbein
Registration No. 25,457

Date: April 27, 2003

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/978,297
				Filing Date	October 17, 2001
				First Named Inventor	Yacoby-Zeevi
				Group Art Unit	1652
				Examiner Name	Richard G. Hutson
Sheet	1	of	1	Attorney Docket Number	01/22716

U.S. PATENT DOCUMENTS						
Examiners Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,968,822		Pecker et al	10-19-1999	

RECEIVED

MAY 01 2003

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AB	Kizaki, et al, Expression of Heparanase mRNA in Bovine Placenta During Gestation, Journal of Reproduction and Fertility, 2001, Vol. 121, pp. 573-580	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.